Key positives include a unique, first-in-class therapeutic concept with broad potential applications, supported by an expanding patent portfolio and FDA Breakthrough Device status in critical disease areas. The balance sheet currently shows solid liquidity and very low debt, which gives the company some operational breathing room. The focus on high unmet-need diseases like advanced cancers, life-threatening viruses, and Long COVID offers the possibility of strong future demand if the technology is proven.

Major risks center on the lack of revenue, ongoing sizable losses, and heavy reliance on new equity financing to stay afloat, as highlighted by going-concern language. Clinical and regulatory risk is high: Hemopurifier still needs to demonstrate clear clinical benefit and gain approval in one or more indications. Competition from established treatments and alternative technologies, combined with a narrow product base and history of shareholder dilution, further raises the stakes. If financing conditions worsen or clinical data disappoint, the company’s viability could be challenged.

The outlook is highly uncertain and hinges on a few key milestones: clinical data from the oncology trial, progress toward additional studies in viral and exosome-driven diseases, and the company’s ability to secure ongoing funding. If data are supportive and capital remains available, Aethlon could gradually transition from a purely research-stage entity toward commercialization. If not, the company may face difficult strategic choices around scaling back programs, restructuring, or seeking partnerships. In the near term, AEMD remains a high-risk, high-uncertainty story driven more by scientific and regulatory events than by traditional operating metrics.